Clinical trials: SGLT2 Inhibitor, active
Osteoarthritis
GLP1 Analogues and the Risk of Osteoarthritis
Assessing the effects of GLP1 RA Vs SGLT2 Inhibitors vs. Standard of care in joint pain, physical function, stiffness, and improving Quality of Life for patients with type 2 diabetes.
- Trial name
- NCT07360457
- Testing
- GLP-1 analog, SGLT2 inhibitor, Antidiabetic
- Volunteers
- 390 people
- Sponsor
- Beni-Suef University
SGLT 2 Inhibitors
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients
To evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) before and after…
- Trial name
- NCT07186153
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Volunteers
- 100 people
- Sponsor
- Assiut University
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Study Background \& Purpose: The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI).
- Conditions
- No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT07898709
- Testing
- Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment
- Where
- 4 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Al-Azhar University
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study
This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- HF-MultiOmics (NCT07355088)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xinjiang Medical University
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes
This study is a multicenter, randomized controlled trial to test whether an SGLT2 inhibitor (dapagliflozin), a type of diabetes medication, can slow down or even reverse the progression of coronary atherosclerosis (plaque buildup…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease, Atherosclerosis
- Trial name
- SCOPE (NCT07614230)
- Testing
- Dapagliflozin (DAPA), Standard Care (Treatment as Usual)
- Where
- 2 sites in China
- Volunteers
- 144 people
- Sponsor
- Junjie Yang
Diabetic Nephropathies, Kidney Failure, Chronic
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes.
- Conditions
- Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
- Trial name
- SUGARNSALT (NCT06217302)
- Testing
- Sotagliflozin
- Where
- 19 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Alessandro Doria
Diabetes Mellitus, Type 2
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose…
- Trial name
- NCT06260722
- Testing
- Retatrutide, Semaglutide
- Where
- 77 sites in United States, Argentina and 3 more
- Volunteers
- 1,250 people
- Sponsor
- Eli Lilly and Company
Acute Heart Failure (AHF)
Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department
Background: SGLT2 inhibitors reduce CHF morbidity/mortality but are underutilized in elderly patients with acute decompensated CHF (ADCHF) admitted outside cardiology departments.
- Trial name
- GlifloFastER (NCT07392788)
- Testing
- Early initiation of dapagliflozin 10mg daily within 24h of emergency department admission, Telephone follow-up by cardiac nurse practitioner at 1 month, Standard acute decompensated heart failure care
- Volunteers
- 144 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
The goal of this clinical trial is to learn whether dapagliflozin can help manage weight gain caused by antipsychotic medications in people aged 16 years or older who are receiving antipsychotic treatment and have developed…
- Trial name
- NCT07342764
- Testing
- Dapagliflozin, Metformin, Common Lifestyle Program
- Where
- Oman
- Volunteers
- 110 people
- Sponsor
- Sultan Qaboos University
Aortic Valve Stenosis, Heart Failure
ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events…
- Trial name
- ENAVO-TAVR (NCT05672836)
- Testing
- Enavogliflozin, Standard-of-Care
- Where
- 31 sites in South Korea
- Volunteers
- 1,040 people
- Sponsor
- Duk-Woo Park, MD
Depression
Dapagliflozin in Depression
Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous.
- Trial name
- NCT07239011
- Testing
- Fluoxetine, Dapagliflozin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
The aim of this clinical trial is to investigate whether dapagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) can reduce levels of coronary inflammation in patients with stage 4 CKM syndrome.
- Trial name
- DAPA-PCAT (NCT07351643)
- Testing
- Dapagliflozin
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shenyang Northern Hospital
Chronic Kidney Disease
SGLT2 Inhibitors and Renal Anemia in Japan: RWD
The objectives of the study are: 1. To evaluate the association between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor use and the occurrence of anemia in patients with chronic kidney disease (CKD) using a nested case-control…
- Trial name
- NCT07063316
- Testing
- SGLT2 inhibitor
- Where
- Japan
- Volunteers
- 15,000 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, SGLT 2 Inhibitors
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
Revised version: Locally advanced or advanced solid tumors remain a major clinical challenge despite multimodal treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.
- Trial name
- SGLT2SOLID (NCT07703163)
- Testing
- Canagliflozin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
Type 2 Diabetes
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2…
- Trial name
- TELOS (NCT06972732)
- Testing
- Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Breast Neoplasms
Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B
In the context of breast cancer, in case of an indication for chemotherapy, anthracycline-based protocols make it possible to improve the overall survival of patients most at risk.
- Trial name
- SCARA-B (NCT06443645)
- Testing
- Anthracycline
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Paul Strauss
Metabolic Syndrome, Obesity & Overweight
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
We investigate the role of empagliflozin in the treatment of obesity in PLWH.
- Conditions
- Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)
- Trial name
- NCT07336797
- Testing
- Empagliflozin (oral)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Abdelrahman Mahmoud
Peripheral Arterial Disease(PAD)
Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
The study is observational and involves patients (pts) with peripheral arterial occlusive disease (PAD) who have undergone lower limb revascularization procedures.
- Trial name
- NCT07157475
- Testing
- Treatment with SGLT2 inhibitors (flozins)
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Wroclaw Medical University
Type 2 Diabetes
SGLTi, Hepatic Glucose Production and Ketogenesis
In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and…
- Trial name
- NCT05960656
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
CAD - Coronary Artery Disease, Inflamation
Effect of Empagliflozin on Inflammation
Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure.
- Conditions
- CAD - Coronary Artery Disease, Inflamation, PCI, SGLT 2 Inhibitors
- Trial name
- EMPANTINFLAM (NCT07292909)
- Testing
- Empagliflozin (SGLT2i)
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Hotel Dieu de France Hospital